In G1 metastatic GEP-NET with small lesions visible on PET dotatate, very low burden of disease on CT and no clinical symptoms, are there any data to suggest early lanreotide changes natural history of disease and prolongs OS vs observation until symptoms?

Answer from: Medical Oncologist at Academic Institution

The answer is no, there is no such data supporting an early intervention. The keywords here are "no clinical symptoms". For patients with functional panc NETs or siNETs with carcinoid syndrome, initiation of somatostatin analog (SSA) therapy is indicated for syndrome control.The NCCN, ENETS, and NAN...

Comments

Medical Oncologist at Montefiore Einstein Comprehensive Cancer Center
Thank you. Would you consider a resected SBO "symp...

Medical Oncologist at Mayo Clinic
I would be careful with a h/o SBO, especially of p...

Please select the option that best describes you:

In G1 metastatic GEP-NET with small lesions visible on PET dotatate, very low burden of disease on CT and no clinical symptoms, are there any data to suggest early lanreotide changes natural history of disease and prolongs OS vs observation until symptoms?

Related Questions